{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:31:50Z","timestamp":1791160310436,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.bcp.2009.05.030","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T08:23:46Z","timestamp":1243671826000},"page":"803-812","source":"Crossref","is-referenced-by-count":126,"title":["TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia"],"prefix":"10.1016","volume":"78","author":[{"given":"T.A.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kucinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.G.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Wersinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.K.","family":"Stachowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Stachowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Papke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Lippiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bencherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.05.030_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-7634(03)00035-6","article-title":"Schizophrenia: from phenomenology to neurobiology","volume":"27","author":"Wong","year":"2003","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bcp.2009.05.030_bib2","first-page":"351","article-title":"Pharmacological strategies for relapse prevention in schizophrenia","volume":"6","author":"Barnes","year":"2007","journal-title":"Psychiatry (England)"},{"key":"10.1016\/j.bcp.2009.05.030_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller d.D.","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.bcp.2009.05.030_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.299.5605.333","article-title":"Neuroscience. Deconstructing schizophrenia","volume":"299","author":"Holden","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bcp.2009.05.030_bib5","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/sj.npp.1300265","article-title":"Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia","volume":"28","author":"Avila","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.npp.1300450","article-title":"Effects of nicotine on cognitive deficits in schizophrenia","volume":"29","author":"Harris","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.npp.1300466","article-title":"Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients","volume":"29","author":"DeLuca","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0893-133X(96)00018-8","article-title":"Nicotine-haloperidol interactions and cognitive performance in schizophrenics","volume":"15","author":"Levin","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0891-0618(00)00109-5","article-title":"The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia","volume":"20","author":"Freedman","year":"2000","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.bcp.2009.05.030_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(00)01144-7","article-title":"Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome","volume":"287","author":"Durany","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2009.05.030_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2009.05.030_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biopsych.2006.03.054","article-title":"Genetics of chromosome 15q13-q14 in schizophrenia","volume":"60","author":"Leonard","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bcp.2009.05.030_bib13","first-page":"171","article-title":"\u03b17 nicotinic receptor agonists as potential therapeutic drugs for schizophrenia","volume":"5","author":"Hashimoto","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bcp.2009.05.030_bib14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1471-4159.2006.03754.x","article-title":"Fibroblast growth factor receptor signaling affects development and function of dopamine neurons\u2014inhibition results in a schizophrenia-like syndrome in transgenic mice","volume":"97","author":"Klejbor","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2009.05.030_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.brainresbull.2006.04.008","article-title":"Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder","volume":"70","author":"Gaughran","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bcp.2009.05.030_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/oxfordjournals.schbul.a033326","article-title":"Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia","volume":"24","author":"Swerdlow","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bcp.2009.05.030_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0028-3908(98)00221-4","article-title":"Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors","volume":"38","author":"Davies","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0026-895X(25)10280-0","article-title":"The binding of l-[3H]nicotine to a single class of high affinity sites in rat brain membranes","volume":"29","author":"Lippiello","year":"1986","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.030_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0022-3565(24)37321-5","article-title":"The heterocyclic substituted pyridine derivative (+\/\u2212)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors","volume":"284","author":"Bencherif","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.030_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.lfs.2005.11.009","article-title":"Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses","volume":"78","author":"Papke","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2009.05.030_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.bjp.0704833","article-title":"Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis","volume":"137","author":"Papke","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.030_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bcp.2009.05.030_bib24","unstructured":"Mazurov A, Klucik J, Miao L, Seamans A, Phillips T, Schmitt J, et al. Inventors. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof. US Patent 6953855; 2005."},{"key":"10.1016\/j.bcp.2009.05.030_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/1568007023339256","article-title":"Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands","volume":"1","author":"Astles","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.bcp.2009.05.030_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.030_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/REVNEURO.1999.10.1.59","article-title":"Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity","volume":"10","author":"Sams-Dodd","year":"1999","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/0269881105057696","article-title":"Dysregulation of thalamic sensory \u201ctransmission\u201d in schizophrenia: neurochemical vulnerability to hallucinations","volume":"20","author":"Behrendt","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bcp.2009.05.030_bib29","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0896-6273(00)00042-8","article-title":"Long-term potentiation of excitatory inputs to brain reward areas by nicotine","volume":"27","author":"Mansvelder","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2009.05.030_bib31","first-page":"61","article-title":"Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model","volume":"21","author":"Liu","year":"2007","journal-title":"Fed Am Soc Exp Biol J"},{"key":"10.1016\/j.bcp.2009.05.030_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/mol.108.046623","article-title":"Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms","volume":"74","author":"Dickinson","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.030_bib33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1460-9568.2008.06077.x","article-title":"Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission","volume":"27","author":"Arnaiz-Cot","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib34","article-title":"Drug discrimination and neurochemical studies in alpha7 null mutant mice: tests for the role of nicotinic alpha7 receptors in dopamine release","author":"Quarta","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.030_bib35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.56.11.1001","article-title":"Gamma frequency-range abnormalities to auditory stimulation in schizophrenia","volume":"56","author":"Kwon","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bcp.2009.05.030_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1096-9861(20000911)425:1<58::AID-CNE6>3.0.CO;2-X","article-title":"Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization","volume":"425","author":"Quik","year":"2000","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.bcp.2009.05.030_bib37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1523\/JNEUROSCI.17-02-00576.1997","article-title":"Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus","volume":"17","author":"Lena","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-9964(94)90067-1","article-title":"Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings","volume":"12","author":"Waldo","year":"1994","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bcp.2009.05.030_bib39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0166-2236(00)01817-8","article-title":"Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?","volume":"24","author":"Sharp","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib40","doi-asserted-by":"crossref","first-page":"28451","DOI":"10.1074\/jbc.M504400200","article-title":"Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation","volume":"280","author":"Fang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.05.030_bib41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/dna.2007.0664","article-title":"Integrative nuclear signaling in cell development\u2014a role for FGF receptor-1","volume":"26","author":"Stachowiak","year":"2007","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.bcp.2009.05.030_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0166-4328(00)00197-2","article-title":"Central nicotinic receptors, neurotrophic factors and neuroprotection","volume":"113","author":"Belluardo","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bcp.2009.05.030_bib43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuroscience.2006.12.012","article-title":"Acute intermittent nicotine treatment induces fibroblast growth factor-2 in the subventricular zone of the adult rat brain and enhances neuronal precursor cell proliferation","volume":"145","author":"Mudo","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2009.05.030_bib44","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cmdc.200600207","article-title":"Central nicotinic receptors: structure, function, ligands, and therapeutic potential","volume":"2","author":"Romanelli","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2009.05.030_bib45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1124\/jpet.104.076968","article-title":"The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats","volume":"312","author":"Hajos","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.030_bib46","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.bmcl.2008.04.070","article-title":"Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity","volume":"18","author":"Acker","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2009.05.030_bib47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents","volume":"321","author":"Boess","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.030_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.npp.1301188","article-title":"SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia","volume":"32","author":"Pichat","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00037.x","article-title":"Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties","volume":"14","author":"Tietje","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bcp.2009.05.030_bib50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00213-003-1482-2","article-title":"DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats","volume":"169","author":"O\u2019Neill","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.030_bib51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.npp.1300028","article-title":"Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers","volume":"28","author":"Kitagawa","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008877-199911000-00014","article-title":"AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats","volume":"10","author":"Levin","year":"1999","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.030_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-003-1668-7","article-title":"AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors","volume":"172","author":"Van","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.030_bib54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00213-001-0927-8","article-title":"Effects of alpha 4\/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice","volume":"159","author":"Schreiber","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2009.05.030_bib55","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1523\/JNEUROSCI.5269-04.2005","article-title":"A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization","volume":"25","author":"Hurst","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2009.05.030_bib56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.107.120436","article-title":"An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo","volume":"323","author":"Timmermann","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.05.030_bib57","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bcp.2009.05.030_bib58","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuropharm.2006.08.023","article-title":"Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors","volume":"52","author":"Singhal","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2009.05.030_bib59","doi-asserted-by":"crossref","unstructured":"Klejbor I, Kucinski A, Wersinger SR, Corso T, Spodnik JH, Dziewi\u0105tkowski J, et al. Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis. Schizophrenia Res. 2009, in press.","DOI":"10.1016\/j.schres.2009.06.006"},{"key":"10.1016\/j.bcp.2009.05.030_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1021\/jm701094q","article-title":"Emerging opportunities for antipsychotic drug discovery in the postgenomic era","volume":"51","author":"Marino","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2009.05.030_bib61","doi-asserted-by":"crossref","unstructured":"Grinevich VP, Papke RL, Lippiello PM, Bencherif M, Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology 2009; doi:10.1016\/j.neuropharm.2009.05.003.","DOI":"10.1016\/j.neuropharm.2009.05.003"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T19:55:44Z","timestamp":1739130944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209004419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0006295209004419"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.05.030","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}